KYDNEY DISFUNTION AND HYPERTENSION – BEYOND THE OBVIOUS

Authors

  • Carolina Midões Interno de Formação Específica em Medicina Interna; Hospital de São José, Centro Hospitalar Universitário de Lisboa Central, CHULC, EPE, Portugal
  • Filipa Cardoso Interno de Formação Específica em Medicina Interna; Hospital de São José, Centro Hospitalar Universitário de Lisboa Central, CHULC, EPE.
  • Teresa Souto Moura Assistente Hospitalar em Medicina Interna; Hospital de São José, Centro Hospitalar Universitário de Lisboa Central, CHULC, EPE

DOI:

https://doi.org/10.58043/rphrc.96

Keywords:

hypertension, chronic kidney disease, renal dysfunction, proteinuria

Abstract

Chronic kidney disease (CKD) is defined as the presence of an estimated glomerular filtration rate (eGFR) of less than 60mL/min/1.73m2 for 3 or more months, regardless of the cause. KDIGO (Kydney Disease Improving Global Outcomes) stages G3 to 5 have a prevalence of about 10% in the adult population. The risk factors that contribute the most to its onset and progression are arterial hypertension (HTN) and diabetes mellitus, and their control is essential for the prevention of CKD.

We present the case of a 48-year-old melanodermic male, with a known history of type II diabetes, poorly controlled hypertension, CKD stage KDIGO G3a (baseline creatinine 1.6 mg/dL, eGFR 48mL/min/1.73) and obesity.
He was referred to the HTN consult due to grade 3 hypertension, under 3 antihypertensive drugs plus a diuretic. The investigation of secondary causes and characterization of target organ damage were carried out. A2 albuminuria, increased urinary protein/creatinine ratio (241.7 mg/gr) and protein electrophoresis with increased gamma globulins were observed. Serum immunofixation detected a monoclonal IgG peak. Multiple myeloma was hypothesized and confirmed by myelogram and bone biopsy. Referred to Clinical Hematology, being without disease progression and under surveillance. The blood pressure profile is controlled with 4 antihypertensive plus a diuretic.

This case aims to alert for the need to investigate secondary causes of HTN in certain clinical conditions, namely in the presence of resistant HTN and worsening of renal function with proteinuria, even in patients probably with essential HTN. Moreover, this case, highlights the relationship and etiology of CKD and HTN. The “obvious” would be CKD as a consequence of diabetic and hypertensive nephropathy, however, the diagnosis may have worsened not only the CKD, but also the HTN itself. The doubt remains, since there is no hematological indication for active treatment.

Downloads

Download data is not yet available.

References

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3:1-150 2. Inker L, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA et al; KDOQI US Commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-735

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al; 2018 ESC/ESH Guidelines for the management of arterial hypertension - The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH); European Heart Journal 2018; 39:3021–31044.

Unger T, Borghi C, Charchar F, Khan NA, Pulter NR, Prabhakaran D et al; 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75:1334–5

Rimoldi F, Scherrer U, Messerli FH; Secondary arterial hypertension: when, who, and how to screen?; European Heart Journal 2014; 35:1245–1254

Rajkumar S, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol. 2014; 15:e538-48

Adam Cuker, Jessica K. Altman, Aaron T. Gerds, Ted Wun.American Society of Hematology Self-Assessment Program, 7th Editions. E-book. 2019

Myeloma.org [homepage na Internet]. International Myeloma Foundation Online Resources; [consultado 30 Abr 2022]. Disponível em: http://www.myeloma.org/. 9. Dinis PG, Cachulo MC, Fernandes A, Paiva L, Gonçalves L; Hipertensão Arterial Sistémica Secundária: Incertezas do Diagnóstico; Acta Med Port 2017; 30(6):493-496

Pugh D, Gallacher P, Dhaun N; Manegement of hypertensio in chronic kidney disease; Drugs. 2019; 79:365-379

Ku E, Lee B, Wei J, Weir M; Hypertension in CKD: Core Curriculum 2019; Am J Kidney Dis. 2019; 74(1):120-131

Parati G, Ochoa JE, Bilo G, Agarwal R, Covic A, Dekker FW et al; Hypertension in chronic kidney disease part 1 – Out-of-office blood pressure monitoring: methods, thresholds and patterns; Hypertension. 2016; 67:1093-1101

Buffet L, Ricchetti C; Chronic kidney disease and hypertension: a destructive combination; US Pharm. 2012; 37(6):26-29

Polychronopoulou E, Wuerzner G, Burnier M; How do I manage hypertension in patients with advanced chronic kidney disease not on dialysis? Perspectives from clinical practice; Vascular Health and Risk Management. 2021; 17:1-11

Tomson CRV, Cheung AK, Mann JFE, Chang TI, Cushman WC, Furth SL et al; Management of blood pressure in patients with chronic kidney disease not receiving dialysis: synopsis of the 2021 KDIGO clinical practice guideline; Ann Intern Med. 2021;1-13.

Published

2023-07-27

How to Cite

1.
Midões C, Cardoso F, Souto Moura T. KYDNEY DISFUNTION AND HYPERTENSION – BEYOND THE OBVIOUS. RH [Internet]. 2023 Jul. 27 [cited 2024 Dec. 22];(96):28-35. Available from: https://revistahipertensao.pt/index.php/rh/article/view/96

Issue

Section

Caso Clínico